Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay
Revvity, Inc. (RVTY)
Company Research
Source: Business Wire
Company expands infectious disease diagnostics portfolio with first of several assays validated for dried blood spots as sample material WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN’s serological infection diagnostics portfolio with validation for dried blood spots (DBS) as sample material in addition to serum and plasma.Measles is a highly contagious airborne disease that can lead to severe complications for infected individuals. With measles cases on the rise globally, improving and expanding access to testing for the measles virus supports broad surveillance and prevention efforts.Diagnostics using DBS only require droplets of capillary blood to provide a re
Show less
Read more
Impact Snapshot
Event Time:
RVTY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVTY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVTY alerts
High impacting Revvity, Inc. news events
Weekly update
A roundup of the hottest topics
RVTY
News
- Revvity to Present at J.P. Morgan Healthcare ConferenceBusiness Wire
- Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials DiscoveryBusiness Wire
- Revvity (NYSE:RVTY) was downgraded by analysts at Bank of America Corporation from a "buy" rating to a "neutral" rating. They now have a $110.00 price target on the stock.MarketBeat
- Revvity (NYSE:RVTY) was given a new $107.00 price target on by analysts at Wells Fargo & Company.MarketBeat
- Revvity (NYSE:RVTY) had its "overweight" rating reaffirmed by analysts at Barclays PLC.MarketBeat
RVTY
Earnings
- 10/27/25 - Beat
RVTY
Sec Filings
- 12/18/25 - Form 4
- 12/17/25 - Form 4
- 11/18/25 - Form NPORT-P
- RVTY's page on the SEC website